Recalibration and Validation of a Risk Scoring Tool to Predict Multidrug-Resistant Pseudomonas aeruginosa

Nhu Le1, Hyunuk Seung2, Megan E Dunning3

  • 1University of Maryland School of Medicine, Baltimore, Maryland, USA.

Insights

A new risk score helps identify difficult-to-treat resistant *Pseudomonas aeruginosa* in intensive care units. While specific, the score needs local validation due to moderate accuracy and low sensitivity for detecting this challenging bacteria.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Microbiology

Background:

  • *Pseudomonas aeruginosa* is a significant cause of hospital-acquired infections.
  • Difficult-to-treat resistant strains pose a growing clinical challenge.
  • Accurate identification of resistant pathogens is crucial for effective treatment.

Purpose of the Study:

  • To recalibrate and evaluate a risk score for identifying difficult-to-treat resistant *Pseudomonas aeruginosa*.
  • To assess the performance of the risk score in an intensive care unit (ICU) population.
  • To provide data for clinical decision-making in managing *Pseudomonas aeruginosa* infections.

Main Methods:

  • Retrospective analysis of 197 ICU patients with *Pseudomonas aeruginosa* bloodstream or respiratory infections.
  • Recalibration of an existing risk score.
  • Evaluation of model discrimination (c-statistic), sensitivity, and specificity.

Main Results:

  • The prevalence of difficult-to-treat resistant *Pseudomonas aeruginosa* was 6%.
  • The recalibrated risk score demonstrated moderate discrimination (c-statistic 0.71-0.74).
  • The model exhibited low sensitivity (18%) but high specificity (94%-96%).

Conclusions:

  • The developed risk score shows potential for identifying difficult-to-treat resistant *Pseudomonas aeruginosa*.
  • The low sensitivity necessitates caution and suggests the score is better for ruling out resistance.
  • Local validation and careful consideration of performance trade-offs are essential before clinical implementation.

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...